| scholarly article | Q13442814 |
| P2093 | author name string | Ulrich Beuers | |
| Karin Dilger | |||
| Malte H J Heeg | |||
| Annette Denk | |||
| P2860 | cites work | Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin | Q28211706 |
| A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group | Q28243457 | ||
| Effects of long-term rifampicin administration in primary biliary cirrhosis | Q28319860 | ||
| The human bile salt export pump: characterization of substrate specificity and identification of inhibitors | Q28612066 | ||
| Genetic variability in CYP3A5 and its possible consequences. | Q30341330 | ||
| Cytochrome P-450 3A4: regulation and role in drug metabolism | Q33636632 | ||
| Review article: mechanisms of action and therapeutic applications of ursodeoxycholic acid in chronic liver diseases | Q33723536 | ||
| Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis | Q33745849 | ||
| Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited | Q34146325 | ||
| Sex is a major determinant of CYP3A4 expression in human liver | Q34265530 | ||
| Ursodeoxycholic acid 'mechanisms of action and clinical use in hepatobiliary disorders'. | Q34330984 | ||
| Regulation of cyp3a gene transcription by the pregnane x receptor | Q34504007 | ||
| The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism? | Q34615575 | ||
| In vitro and in vivo drug interactions involving human CYP3A. | Q34663451 | ||
| Extrahepatic manifestations of cholestasis | Q34776437 | ||
| Review article: pruritus in cholestatic and other liver diseases | Q35091959 | ||
| Pharmacokinetic interactions with rifampicin : clinical relevance | Q35185727 | ||
| Urinary 6?-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals | Q35579020 | ||
| The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis | Q40737262 | ||
| Antiepileptic drugs increase plasma levels of 4beta-hydroxycholesterol in humans: evidence for involvement of cytochrome p450 3A4. | Q40784945 | ||
| Disrupted bile acid homeostasis reveals an unexpected interaction among nuclear hormone receptors, transporters, and cytochrome P450. | Q40785589 | ||
| The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin | Q40851439 | ||
| Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis | Q40883127 | ||
| Identification of budesonide and prednisone as substrates of the intestinal drug efflux pump P-glycoprotein | Q42468905 | ||
| Ursodeoxycholic acid (UDCA) prevents DCA effects on male mouse liver via up-regulation of CYP [correction of CXP] and preservation of BSEP activities | Q44080027 | ||
| Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis | Q44493764 | ||
| The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity | Q44579595 | ||
| Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens | Q44787212 | ||
| The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. | Q51521480 | ||
| Changes in the expression and localization of hepatocellular transporters and radixin in primary biliary cirrhosis. | Q52552319 | ||
| Validation of a fatigue impact score in primary biliary cirrhosis: towards a standard for clinical and trial use. | Q52920374 | ||
| Bile acid structure and selective modulation of murine hepatic cytochrome P450-linked enzymes | Q57012049 | ||
| Simultaneous determination of urinary free cortisol and 6β-hydroxycortisol by high-performance liquid chromatography to measure human CYP3A activity | Q61794839 | ||
| Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial | Q68019501 | ||
| Ursodeoxycholic acid in primary biliary cirrhosis: results of a controlled double-blind trial | Q69357047 | ||
| Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin | Q71650801 | ||
| Ursodeoxycholic acid in the treatment of primary biliary cirrhosis | Q72401649 | ||
| Time course of the changes in prednisolone pharmacokinetics after co-administration or discontinuation of rifampin | Q72693322 | ||
| Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial | Q73026352 | ||
| Ursodeoxycholic acid for primary biliary cirrhosis | Q73497916 | ||
| Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver | Q73715566 | ||
| Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis. The UDCA-PBC Study Group | Q77807948 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | primary biliary cholangitis | Q1072420 |
| P304 | page(s) | 595-602 | |
| P577 | publication date | 2005-03-01 | |
| P1433 | published in | Hepatology | Q15724398 |
| P1476 | title | No relevant effect of ursodeoxycholic acid on cytochrome P450 3A metabolism in primary biliary cirrhosis | |
| P478 | volume | 41 |
| Q33866454 | Concept on the pathogenesis and treatment of primary biliary cirrhosis |
| Q36495172 | Drug insight: Mechanisms and sites of action of ursodeoxycholic acid in cholestasis |
| Q64939082 | Drug-Drug Interactions of Infectious Disease Treatments in Low-Income Countries: A Neglected Topic? |
| Q40183754 | Expression of bile acid synthesis and detoxification enzymes and the alternative bile acid efflux pump MRP4 in patients with primary biliary cirrhosis |
| Q46716764 | Influence of CYP3A4, CYP3A5, and ABCB1 genotype and expression on budesonide pharmacokinetics: a possible role of intestinal CYP3A4 expression |
| Q38774857 | Management of cholestatic disease in 2017. |
| Q34017604 | Medical treatment of cholestatic liver diseases: From pathobiology to pharmacological targets |
| Q37254347 | Medical treatment of primary sclerosing cholangitis: a role for novel bile acids and other (post-)transcriptional modulators? |
| Q35741546 | New perspectives for the treatment of cholestasis: lessons from basic science applied clinically |
| Q46940563 | Nuclear receptors, bile-acid detoxification, and cholestasis |
| Q84230884 | Primary biliary cirrhosis |
| Q37841609 | The impact of cholesterol and its metabolites on drug metabolism |
| Q37919924 | Ursodeoxycholic acid in cholestasis: linking action mechanisms to therapeutic applications. |
Search more.